No Data
No Data
Kangbo Medical-B (02216.HK): Sun Jiaen has been appointed as the company secretary, legal process document agent and authorized representative.
On June 25, Gelonhui announced that He Yanqun had resigned as the company secretary, legal document agent, and authorized representative, effective from June 25, 2024. Sun Jiaen has been appointed as the new representative of Fangyuan to replace Ms. He as the company secretary, legal document agent, and authorized representative, effective from June 25, 2024.
Kunbo Medical-B (02216.HK) grants 797,000 reward shares
Gelonghui, May 30, 丨 Kunbo Medical-B (02216.HK) announced that on May 30, 2024, the company awarded 797,241 awards (the same as the number of relevant shares, and approximately 0.15% of the total number of shares issued on the date of this announcement) to 4 grantees in accordance with the terms of the restricted share unit plan. The purpose of awarding rewards is to reward the grantor's performance and contribution to the Group, to align the interests of the grantor with those of the Group through ownership of shares, dividends and other share distributions and/or share appreciation, and to encourage and retain the grantor to contribute to the Group's long-term growth and profits.
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
BRONCUS-B: Annual Report 2023
Kunbo Medical-B (02216) appoints Xu Hong as chairman
Kunbo Medical-B (02216) announced that since April 19, 2024, Zhao Yiwei has resigned as a non-executive director,...
Kunbo Healthcare (02216.HK) Announces 2023 Annual Results
The development of lung disease treatment products continues to lead, and product sales are steadily advancing in Hangzhou, March 28, 2024/PRNewswire/ -- On March 28, 2024, Kunbo Medical (02216.HK), a leader in precise interventional diagnosis and treatment of lung diseases in China, announced its annual results for the year ended December 31, 2023. During the reporting period, the company achieved product sales revenue of US$12.41 million, an increase of 32% over the previous year. Among them, the total sales revenue of products in mainland China was US$8.62 million, up 48% year on year. In 2023, the company will have a firm industrial layout around “navigation-diagnosis-treatment”, and it will expand
No Data
102768097 : how to do?